Dobutamine	B:C0949700
Stress	I:C0949700
Echocardiography	I:C0949700
:	O
Impact	O
of	O
Abnormal	O
Blood	O
Potassium	I:C1261540
Levels	I:C1261540
on	O
Cardiac	O
Arrhythmias	I:C0003811
.	O

Dobutamine	O
Stress	I:C0949700
Echocardiography	I:C0949700
:	O
Impact	O
of	O
Abnormal	B:C0205161
Blood	O
Potassium	I:C1261540
Levels	I:C1261540
on	O
Cardiac	O
Arrhythmias	I:C0003811
.	O

Dobutamine	O
Stress	I:C0949700
Echocardiography	I:C0949700
:	O
Impact	O
of	O
Abnormal	O
Blood	B:C1261540
Potassium	I:C1261540
Levels	I:C1261540
on	O
Cardiac	O
Arrhythmias	I:C0003811
.	O

Dobutamine	O
Stress	I:C0949700
Echocardiography	I:C0949700
:	O
Impact	O
of	O
Abnormal	O
Blood	O
Potassium	I:C1261540
Levels	I:C1261540
on	O
Cardiac	B:C0003811
Arrhythmias	I:C0003811
.	O

Guidelines	B:C0162791
suggest	O
that	O
an	O
abnormal	O
blood	O
potassium	I:C1261540
level	I:C1261540
is	O
a	O
relative	O
contraindication	O
to	O
performing	O
dobutamine	O
stress	I:C0949700
echocardiography	I:C0949700
(	O
dobutamine	O
stress	I:C0949700
echocardiography	I:C0949700
)	O
.	O

Guidelines	O
suggest	O
that	O
an	O
abnormal	B:C0205161
blood	O
potassium	I:C1261540
level	I:C1261540
is	O
a	O
relative	O
contraindication	O
to	O
performing	O
dobutamine	O
stress	I:C0949700
echocardiography	I:C0949700
(	O
dobutamine	O
stress	I:C0949700
echocardiography	I:C0949700
)	O
.	O

Guidelines	O
suggest	O
that	O
an	O
abnormal	O
blood	B:C1261540
potassium	I:C1261540
level	I:C1261540
is	O
a	O
relative	O
contraindication	O
to	O
performing	O
dobutamine	O
stress	I:C0949700
echocardiography	I:C0949700
(	O
dobutamine	O
stress	I:C0949700
echocardiography	I:C0949700
)	O
.	O

Guidelines	O
suggest	O
that	O
an	O
abnormal	O
blood	O
potassium	I:C1261540
level	I:C1261540
is	O
a	O
relative	O
contraindication	O
to	O
performing	O
dobutamine	B:C0949700
stress	I:C0949700
echocardiography	I:C0949700
(	O
dobutamine	O
stress	I:C0949700
echocardiography	I:C0949700
)	O
.	O

Guidelines	O
suggest	O
that	O
an	O
abnormal	O
blood	O
potassium	I:C1261540
level	I:C1261540
is	O
a	O
relative	O
contraindication	O
to	O
performing	O
dobutamine	O
stress	I:C0949700
echocardiography	I:C0949700
(	O
dobutamine	B:C0949700
stress	I:C0949700
echocardiography	I:C0949700
)	O
.	O

We	O
reviewed	O
a	O
consecutive	B:C2985408
series	I:C2985408
of	I:C2985408
patients	I:C2985408
who	O
had	O
potassium	O
testing	O
within	O
48	O
hours	O
of	O
undergoing	O
dobutamine	O
stress	I:C0949700
echocardiography	I:C0949700
for	O
the	O
evaluation	O
of	O
myocardial	O
ischemia	I:C0151744
over	O
a	O
10	O
-	O
year	O
period	O
(	O
N	O
=	O
13,198	O
)	O
.	O

We	O
reviewed	O
a	O
consecutive	O
series	I:C2985408
of	I:C2985408
patients	I:C2985408
who	O
had	O
potassium	B:C0032821
testing	O
within	O
48	O
hours	O
of	O
undergoing	O
dobutamine	O
stress	I:C0949700
echocardiography	I:C0949700
for	O
the	O
evaluation	O
of	O
myocardial	O
ischemia	I:C0151744
over	O
a	O
10	O
-	O
year	O
period	O
(	O
N	O
=	O
13,198	O
)	O
.	O

We	O
reviewed	O
a	O
consecutive	O
series	I:C2985408
of	I:C2985408
patients	I:C2985408
who	O
had	O
potassium	O
testing	O
within	O
48	O
hours	O
of	O
undergoing	O
dobutamine	B:C0949700
stress	I:C0949700
echocardiography	I:C0949700
for	O
the	O
evaluation	O
of	O
myocardial	O
ischemia	I:C0151744
over	O
a	O
10	O
-	O
year	O
period	O
(	O
N	O
=	O
13,198	O
)	O
.	O

We	O
reviewed	O
a	O
consecutive	O
series	I:C2985408
of	I:C2985408
patients	I:C2985408
who	O
had	O
potassium	O
testing	O
within	O
48	O
hours	O
of	O
undergoing	O
dobutamine	O
stress	I:C0949700
echocardiography	I:C0949700
for	O
the	O
evaluation	B:C0220825
of	O
myocardial	O
ischemia	I:C0151744
over	O
a	O
10	O
-	O
year	O
period	O
(	O
N	O
=	O
13,198	O
)	O
.	O

We	O
reviewed	O
a	O
consecutive	O
series	I:C2985408
of	I:C2985408
patients	I:C2985408
who	O
had	O
potassium	O
testing	O
within	O
48	O
hours	O
of	O
undergoing	O
dobutamine	O
stress	I:C0949700
echocardiography	I:C0949700
for	O
the	O
evaluation	O
of	O
myocardial	B:C0151744
ischemia	I:C0151744
over	O
a	O
10	O
-	O
year	O
period	O
(	O
N	O
=	O
13,198	O
)	O
.	O

Normal	O
potassium	B:C0032821
range	O
in	O
our	O
laboratory	O
is	O
3.6	O
-	O
5.2	O
mmol	O
/	O
L.	O

Normal	O
potassium	O
range	O
in	O
our	O
laboratory	B:C0022877
is	O
3.6	O
-	O
5.2	O
mmol	O
/	O
L.	O

Hemolyzed	B:C0475880
samples	I:C0475880
were	O
not	O
included	O
.	O

The	O
association	O
of	O
potassium	B:C0428289
levels	I:C0428289
with	O
the	O
development	O
of	O
supraventricular	O
and	O
ventricular	O
arrhythmias	I:C0085612
was	O
assessed	O
.	O

The	O
association	O
of	O
potassium	O
levels	I:C0428289
with	O
the	O
development	O
of	O
supraventricular	B:C0428974
and	O
ventricular	O
arrhythmias	I:C0085612
was	O
assessed	O
.	O

The	O
association	O
of	O
potassium	O
levels	I:C0428289
with	O
the	O
development	O
of	O
supraventricular	O
and	O
ventricular	B:C0085612
arrhythmias	I:C0085612
was	O
assessed	O
.	O

The	O
incidence	O
of	O
clinically	O
significant	O
arrhythmias	B:C0003811
was	O
very	O
low	O
(	O
supraventricular	O
tachycardia	I:C0039240
/	O
atrial	O
fibrillation	I:C0004238
,	O
4.9	O
%	O
;	O
nonsustained	O
ventricular	I:C2919575
tachycardia	I:C2919575
,	O
2.9	O
%	O
;	O
sustained	O
ventricular	I:C0750197
tachycardia	I:C0750197
or	O
ventricular	O
fibrillation	I:C0042510
,	O
0.1	O
%	O
)	O
,	O
confirming	O
the	O
overall	O
safety	O
of	O
dobutamine	O
stress	I:C0949700
echocardiography	I:C0949700
.	O

The	O
incidence	O
of	O
clinically	O
significant	O
arrhythmias	O
was	O
very	O
low	O
(	O
supraventricular	B:C0039240
tachycardia	I:C0039240
/	O
atrial	O
fibrillation	I:C0004238
,	O
4.9	O
%	O
;	O
nonsustained	O
ventricular	I:C2919575
tachycardia	I:C2919575
,	O
2.9	O
%	O
;	O
sustained	O
ventricular	I:C0750197
tachycardia	I:C0750197
or	O
ventricular	O
fibrillation	I:C0042510
,	O
0.1	O
%	O
)	O
,	O
confirming	O
the	O
overall	O
safety	O
of	O
dobutamine	O
stress	I:C0949700
echocardiography	I:C0949700
.	O

The	O
incidence	O
of	O
clinically	O
significant	O
arrhythmias	O
was	O
very	O
low	O
(	O
supraventricular	O
tachycardia	I:C0039240
/	O
atrial	B:C0004238
fibrillation	I:C0004238
,	O
4.9	O
%	O
;	O
nonsustained	O
ventricular	I:C2919575
tachycardia	I:C2919575
,	O
2.9	O
%	O
;	O
sustained	O
ventricular	I:C0750197
tachycardia	I:C0750197
or	O
ventricular	O
fibrillation	I:C0042510
,	O
0.1	O
%	O
)	O
,	O
confirming	O
the	O
overall	O
safety	O
of	O
dobutamine	O
stress	I:C0949700
echocardiography	I:C0949700
.	O

The	O
incidence	O
of	O
clinically	O
significant	O
arrhythmias	O
was	O
very	O
low	O
(	O
supraventricular	O
tachycardia	I:C0039240
/	O
atrial	O
fibrillation	I:C0004238
,	O
4.9	O
%	O
;	O
nonsustained	B:C2919575
ventricular	I:C2919575
tachycardia	I:C2919575
,	O
2.9	O
%	O
;	O
sustained	O
ventricular	I:C0750197
tachycardia	I:C0750197
or	O
ventricular	O
fibrillation	I:C0042510
,	O
0.1	O
%	O
)	O
,	O
confirming	O
the	O
overall	O
safety	O
of	O
dobutamine	O
stress	I:C0949700
echocardiography	I:C0949700
.	O

The	O
incidence	O
of	O
clinically	O
significant	O
arrhythmias	O
was	O
very	O
low	O
(	O
supraventricular	O
tachycardia	I:C0039240
/	O
atrial	O
fibrillation	I:C0004238
,	O
4.9	O
%	O
;	O
nonsustained	O
ventricular	I:C2919575
tachycardia	I:C2919575
,	O
2.9	O
%	O
;	O
sustained	B:C0750197
ventricular	I:C0750197
tachycardia	I:C0750197
or	O
ventricular	O
fibrillation	I:C0042510
,	O
0.1	O
%	O
)	O
,	O
confirming	O
the	O
overall	O
safety	O
of	O
dobutamine	O
stress	I:C0949700
echocardiography	I:C0949700
.	O

The	O
incidence	O
of	O
clinically	O
significant	O
arrhythmias	O
was	O
very	O
low	O
(	O
supraventricular	O
tachycardia	I:C0039240
/	O
atrial	O
fibrillation	I:C0004238
,	O
4.9	O
%	O
;	O
nonsustained	O
ventricular	I:C2919575
tachycardia	I:C2919575
,	O
2.9	O
%	O
;	O
sustained	O
ventricular	I:C0750197
tachycardia	I:C0750197
or	O
ventricular	B:C0042510
fibrillation	I:C0042510
,	O
0.1	O
%	O
)	O
,	O
confirming	O
the	O
overall	O
safety	O
of	O
dobutamine	O
stress	I:C0949700
echocardiography	I:C0949700
.	O

The	O
incidence	O
of	O
clinically	O
significant	O
arrhythmias	O
was	O
very	O
low	O
(	O
supraventricular	O
tachycardia	I:C0039240
/	O
atrial	O
fibrillation	I:C0004238
,	O
4.9	O
%	O
;	O
nonsustained	O
ventricular	I:C2919575
tachycardia	I:C2919575
,	O
2.9	O
%	O
;	O
sustained	O
ventricular	I:C0750197
tachycardia	I:C0750197
or	O
ventricular	O
fibrillation	I:C0042510
,	O
0.1	O
%	O
)	O
,	O
confirming	O
the	O
overall	O
safety	O
of	O
dobutamine	B:C0949700
stress	I:C0949700
echocardiography	I:C0949700
.	O

Most	O
arrhythmias	B:C0003811
(	O
88	O
%	O
)	O
occurred	O
in	O
patients	O
with	O
normal	O
potassium	O
levels	I:C0428289
,	O
and	O
arrhythmia	O
rates	O
remained	O
low	O
in	O
patients	O
with	O
potassium	O
abnormalities	O
.	O

Most	O
arrhythmias	O
(	O
88	O
%	O
)	O
occurred	O
in	O
patients	O
with	O
normal	O
potassium	B:C0428289
levels	I:C0428289
,	O
and	O
arrhythmia	O
rates	O
remained	O
low	O
in	O
patients	O
with	O
potassium	O
abnormalities	O
.	O

Most	O
arrhythmias	O
(	O
88	O
%	O
)	O
occurred	O
in	O
patients	O
with	O
normal	O
potassium	O
levels	I:C0428289
,	O
and	O
arrhythmia	B:C0003811
rates	O
remained	O
low	O
in	O
patients	O
with	O
potassium	O
abnormalities	O
.	O

Most	O
arrhythmias	O
(	O
88	O
%	O
)	O
occurred	O
in	O
patients	O
with	O
normal	O
potassium	O
levels	I:C0428289
,	O
and	O
arrhythmia	O
rates	O
remained	O
low	O
in	O
patients	O
with	O
potassium	B:C0032821
abnormalities	O
.	O

Most	O
arrhythmias	O
(	O
88	O
%	O
)	O
occurred	O
in	O
patients	O
with	O
normal	O
potassium	O
levels	I:C0428289
,	O
and	O
arrhythmia	O
rates	O
remained	O
low	O
in	O
patients	O
with	O
potassium	O
abnormalities	B:C1704258
.	O

Patients	O
with	O
hyperkalemia	B:C0020461
had	O
a	O
lower	O
risk	O
of	O
developing	O
mild	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
0.39	O
;	O
95	O
%	O
CI	O
,	O
0.22-0.71	O
)	O
and	O
severe	O
(	O
OR	O
,	O
0.13	O
;	O
95	O
%	O
CI	O
,	O
0.01	O
-	O
0.68	O
)	O
supraventricular	O
arrhythmias	I:C0428974
as	O
well	O
as	O
mild	O
ventricular	O
arrhythmias	I:C0085612
(	O
OR	O
,	O
0.58	O
;	O
95	O
%	O
CI	O
,	O
0.40	O
-	O
0.83	O
)	O
.	O

Patients	O
with	O
hyperkalemia	O
had	O
a	O
lower	O
risk	O
of	O
developing	O
mild	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
0.39	O
;	O
95	O
%	O
CI	O
,	O
0.22-0.71	O
)	O
and	O
severe	O
(	O
OR	O
,	O
0.13	O
;	O
95	O
%	O
CI	O
,	O
0.01	O
-	O
0.68	O
)	O
supraventricular	B:C0428974
arrhythmias	I:C0428974
as	O
well	O
as	O
mild	O
ventricular	O
arrhythmias	I:C0085612
(	O
OR	O
,	O
0.58	O
;	O
95	O
%	O
CI	O
,	O
0.40	O
-	O
0.83	O
)	O
.	O

Patients	O
with	O
hyperkalemia	O
had	O
a	O
lower	O
risk	O
of	O
developing	O
mild	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
0.39	O
;	O
95	O
%	O
CI	O
,	O
0.22-0.71	O
)	O
and	O
severe	O
(	O
OR	O
,	O
0.13	O
;	O
95	O
%	O
CI	O
,	O
0.01	O
-	O
0.68	O
)	O
supraventricular	O
arrhythmias	I:C0428974
as	O
well	O
as	O
mild	O
ventricular	B:C0085612
arrhythmias	I:C0085612
(	O
OR	O
,	O
0.58	O
;	O
95	O
%	O
CI	O
,	O
0.40	O
-	O
0.83	O
)	O
.	O

Even	O
though	O
events	O
were	O
rare	O
,	O
patients	O
with	O
severe	O
hypokalemia	B:C0020621
(	O
potassium	O
levels	I:C0428289
≤	O
3.1	O
mmol	O
/	O
L	O
)	O
had	O
an	O
increased	O
risk	O
of	O
supraventricular	O
arrhythmia	I:C0428974
and	O
ventricular	O
ectopy	I:C0012634
.	O

Even	O
though	O
events	O
were	O
rare	O
,	O
patients	O
with	O
severe	O
hypokalemia	O
(	O
potassium	B:C0428289
levels	I:C0428289
≤	O
3.1	O
mmol	O
/	O
L	O
)	O
had	O
an	O
increased	O
risk	O
of	O
supraventricular	O
arrhythmia	I:C0428974
and	O
ventricular	O
ectopy	I:C0012634
.	O

Even	O
though	O
events	O
were	O
rare	O
,	O
patients	O
with	O
severe	O
hypokalemia	O
(	O
potassium	O
levels	I:C0428289
≤	O
3.1	O
mmol	O
/	O
L	O
)	O
had	O
an	O
increased	O
risk	O
of	O
supraventricular	B:C0428974
arrhythmia	I:C0428974
and	O
ventricular	O
ectopy	I:C0012634
.	O

Even	O
though	O
events	O
were	O
rare	O
,	O
patients	O
with	O
severe	O
hypokalemia	O
(	O
potassium	O
levels	I:C0428289
≤	O
3.1	O
mmol	O
/	O
L	O
)	O
had	O
an	O
increased	O
risk	O
of	O
supraventricular	O
arrhythmia	I:C0428974
and	O
ventricular	B:C0012634
ectopy	I:C0012634
.	O

dobutamine	B:C0949700
stress	I:C0949700
echocardiography	I:C0949700
is	O
safe	O
even	O
in	O
the	O
setting	O
of	O
abnormalities	O
in	O
blood	O
potassium	I:C1261540
concentrations	I:C1261540
,	O
and	O
hence	O
cancellation	O
of	O
dobutamine	O
stress	I:C0949700
echocardiography	I:C0949700
in	O
patients	O
with	O
potassium	O
abnormalities	O
does	O
not	O
appear	O
warranted	O
.	O

dobutamine	O
stress	I:C0949700
echocardiography	I:C0949700
is	O
safe	O
even	O
in	O
the	O
setting	O
of	O
abnormalities	B:C1704258
in	O
blood	O
potassium	I:C1261540
concentrations	I:C1261540
,	O
and	O
hence	O
cancellation	O
of	O
dobutamine	O
stress	I:C0949700
echocardiography	I:C0949700
in	O
patients	O
with	O
potassium	O
abnormalities	O
does	O
not	O
appear	O
warranted	O
.	O

dobutamine	O
stress	I:C0949700
echocardiography	I:C0949700
is	O
safe	O
even	O
in	O
the	O
setting	O
of	O
abnormalities	O
in	O
blood	B:C1261540
potassium	I:C1261540
concentrations	I:C1261540
,	O
and	O
hence	O
cancellation	O
of	O
dobutamine	O
stress	I:C0949700
echocardiography	I:C0949700
in	O
patients	O
with	O
potassium	O
abnormalities	O
does	O
not	O
appear	O
warranted	O
.	O

dobutamine	O
stress	I:C0949700
echocardiography	I:C0949700
is	O
safe	O
even	O
in	O
the	O
setting	O
of	O
abnormalities	O
in	O
blood	O
potassium	I:C1261540
concentrations	I:C1261540
,	O
and	O
hence	O
cancellation	O
of	O
dobutamine	B:C0949700
stress	I:C0949700
echocardiography	I:C0949700
in	O
patients	O
with	O
potassium	O
abnormalities	O
does	O
not	O
appear	O
warranted	O
.	O

dobutamine	O
stress	I:C0949700
echocardiography	I:C0949700
is	O
safe	O
even	O
in	O
the	O
setting	O
of	O
abnormalities	O
in	O
blood	O
potassium	I:C1261540
concentrations	I:C1261540
,	O
and	O
hence	O
cancellation	O
of	O
dobutamine	O
stress	I:C0949700
echocardiography	I:C0949700
in	O
patients	O
with	O
potassium	B:C0032821
abnormalities	O
does	O
not	O
appear	O
warranted	O
.	O

dobutamine	O
stress	I:C0949700
echocardiography	I:C0949700
is	O
safe	O
even	O
in	O
the	O
setting	O
of	O
abnormalities	O
in	O
blood	O
potassium	I:C1261540
concentrations	I:C1261540
,	O
and	O
hence	O
cancellation	O
of	O
dobutamine	O
stress	I:C0949700
echocardiography	I:C0949700
in	O
patients	O
with	O
potassium	O
abnormalities	B:C1704258
does	O
not	O
appear	O
warranted	O
.	O

Elevated	O
potassium	B:C0428289
levels	I:C0428289
are	O
associated	O
with	O
lower	O
rates	O
of	O
clinically	O
significant	O
supraventricular	O
and	O
ventricular	O
arrhythmias	I:C0085612
.	O

Elevated	O
potassium	O
levels	I:C0428289
are	O
associated	O
with	O
lower	O
rates	O
of	O
clinically	O
significant	O
supraventricular	B:C0428974
and	O
ventricular	O
arrhythmias	I:C0085612
.	O

Elevated	O
potassium	O
levels	I:C0428289
are	O
associated	O
with	O
lower	O
rates	O
of	O
clinically	O
significant	O
supraventricular	O
and	O
ventricular	B:C0085612
arrhythmias	I:C0085612
.	O

While	O
remaining	O
at	O
relatively	O
low	O
risk	O
,	O
patients	O
with	O
very	O
low	O
potassium	B:C0428289
levels	I:C0428289
(	O
≤3.1	O
mmol	O
/	O
L	O
)	O
at	O
the	O
time	O
of	O
dobutamine	O
stress	I:C0949700
echocardiography	I:C0949700
have	O
a	O
modestly	O
increased	O
risk	O
of	O
arrhythmia	O
.	O

While	O
remaining	O
at	O
relatively	O
low	O
risk	O
,	O
patients	O
with	O
very	O
low	O
potassium	O
levels	I:C0428289
(	O
≤3.1	O
mmol	O
/	O
L	O
)	O
at	O
the	O
time	O
of	O
dobutamine	B:C0949700
stress	I:C0949700
echocardiography	I:C0949700
have	O
a	O
modestly	O
increased	O
risk	O
of	O
arrhythmia	O
.	O

While	O
remaining	O
at	O
relatively	O
low	O
risk	O
,	O
patients	O
with	O
very	O
low	O
potassium	O
levels	I:C0428289
(	O
≤3.1	O
mmol	O
/	O
L	O
)	O
at	O
the	O
time	O
of	O
dobutamine	O
stress	I:C0949700
echocardiography	I:C0949700
have	O
a	O
modestly	O
increased	O
risk	O
of	O
arrhythmia	B:C0003811
.	O

Consideration	O
could	O
be	O
given	O
to	O
correcting	O
severe	O
hypokalemia	B:C0020621
prior	O
to	O
dobutamine	O
stress	I:C0949700
echocardiography	I:C0949700
.	O

Consideration	O
could	O
be	O
given	O
to	O
correcting	O
severe	O
hypokalemia	O
prior	O
to	O
dobutamine	B:C0949700
stress	I:C0949700
echocardiography	I:C0949700
.	O

